A single injection of a redesigned immune-stimulating antibody directly into a tumor was linked to shrinkage not only at the ...

Over the past 20 years, a class of anticancer drugs called CD40 agonist antibodies has shown great promise but also induced great disappointment. While such drugs have been effective at activating the ...

Treatment with the investigational CD40 ligand inhibitor frexalimab significantly reduced new MRI lesions in relapsing multiple sclerosis (MS) by week 24, according to data presented at the joint ...

Future studies may look at targeting the CD40 pathway as a potential therapeutic target ORLANDO, DECEMBER 7, 2025 - Researchers at The University of Texas MD Anderson Cancer Center have characterized ...

Metastatic cancer is often difficult to treat as it spreads to nearby organs and body parts. For decades, drugs that supercharged the immune system’s response to tumors seemed promising, but in ...

CHICAGO -- The investigational CD40 agonist mitazalimab and modified FOLFIRINOX demonstrated encouraging activity in patients with previously untreated metastatic pancreatic ductal adenocarcinoma, ...

A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers. Use of a tissue-free epigenomic circulating tumor DNA (ctDNA) assay for ...

Cancer treatment single injection results: A redesigned immunotherapy, injected directly into tumors, has shown remarkable results in an early-stage trial. This approach triggered a body-wide immune ...